These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
166 related articles for article (PubMed ID: 32295687)
61. Molecular properties of WHO essential drugs and provisional biopharmaceutical classification. Kasim NA; Whitehouse M; Ramachandran C; Bermejo M; Lennernäs H; Hussain AS; Junginger HE; Stavchansky SA; Midha KK; Shah VP; Amidon GL Mol Pharm; 2004 Jan; 1(1):85-96. PubMed ID: 15832504 [TBL] [Abstract][Full Text] [Related]
62. State of the Art and Uses for the Biopharmaceutics Drug Disposition Classification System (BDDCS): New Additions, Revisions, and Citation References. Bocci G; Oprea TI; Benet LZ AAPS J; 2022 Feb; 24(2):37. PubMed ID: 35199251 [TBL] [Abstract][Full Text] [Related]
63. Effect on the Gastrointestinal Absorption of Drugs from Different Classes in the Biopharmaceutics Classification System, When Treating with Liraglutide. Malm-Erjefält M; Ekblom M; Vouis J; Zdravkovic M; Lennernäs H Mol Pharm; 2015 Nov; 12(11):4166-73. PubMed ID: 26426736 [TBL] [Abstract][Full Text] [Related]
64. Prediction of pH-Dependent Drug-Drug Interactions for Basic Drugs Using Physiologically Based Biopharmaceutics Modeling: Industry Case Studies. Mitra A; Parrott N; Miller N; Lloyd R; Tistaert C; Heimbach T; Ji Y; Kesisoglou F J Pharm Sci; 2020 Mar; 109(3):1380-1394. PubMed ID: 31778721 [TBL] [Abstract][Full Text] [Related]
65. Solubility-Permeability Interplay in Facilitating the Prediction of Drug Disposition Routes, Extent of Absorption, Food Effects, Brain Penetration and Drug Induced Liver Injury Potential. Benet LZ J Pharm Sci; 2023 Sep; 112(9):2326-2331. PubMed ID: 37429358 [TBL] [Abstract][Full Text] [Related]
66. Biopharmaceutical optimization in neglected diseases for paediatric patients by applying the provisional paediatric biopharmaceutical classification system. Del Moral Sanchez JM; Gonzalez-Alvarez I; Cerda-Revert A; Gonzalez-Alvarez M; Navarro-Ruiz A; Amidon GL; Bermejo M Br J Clin Pharmacol; 2018 Oct; 84(10):2231-2241. PubMed ID: 29846973 [TBL] [Abstract][Full Text] [Related]
67. The biopharmaceutics classification system (BCS): class III drugs - better candidates for BA/BE waiver? Blume HH; Schug BS Eur J Pharm Sci; 1999 Dec; 9(2):117-21. PubMed ID: 10620723 [TBL] [Abstract][Full Text] [Related]
68. Scientific considerations concerning the EMA change in the definition of "dose" of the BCS-based biowaiver guideline and implications for bioequivalence. Daousani C; Macheras P Int J Pharm; 2015 Jan; 478(2):606-9. PubMed ID: 25437115 [TBL] [Abstract][Full Text] [Related]
69. Biopharmaceutics classification by high throughput solubility assay and PAMPA. Obata K; Sugano K; Machida M; Aso Y Drug Dev Ind Pharm; 2004 Feb; 30(2):181-5. PubMed ID: 15089052 [TBL] [Abstract][Full Text] [Related]
70. Analysis of five active ingredients of Er-Zhi-Wan, a traditional Chinese medicine water-honeyed pill, using the biopharmaceutics classification system. Cao X; Li H; Wang M; Ren X; Deng Y Biomed Chromatogr; 2020 Feb; 34(2):e4757. PubMed ID: 31755125 [TBL] [Abstract][Full Text] [Related]
71. Pharmaceutical product development technologies based on the biopharmaceutical classification system. Jain D; Pathak D; Pathak K Pharmazie; 2009 Aug; 64(8):483-90. PubMed ID: 19746834 [TBL] [Abstract][Full Text] [Related]
72. Formulation design for poorly water-soluble drugs based on biopharmaceutics classification system: basic approaches and practical applications. Kawabata Y; Wada K; Nakatani M; Yamada S; Onoue S Int J Pharm; 2011 Nov; 420(1):1-10. PubMed ID: 21884771 [TBL] [Abstract][Full Text] [Related]
74. A perspective for biowaivers of human bioequivalence studies on the basis of the combination of the ratio of AUC to the dose and the biopharmaceutics classification system. Sakuma S; Tachiki H; Uchiyama H; Fukui Y; Takeuchi N; Kumamoto K; Satoh T; Yamamoto Y; Ishii E; Sakai Y; Takeuchi S; Sugita M; Yamashita S Mol Pharm; 2011 Aug; 8(4):1113-9. PubMed ID: 21630662 [TBL] [Abstract][Full Text] [Related]
75. Human in vivo regional intestinal permeability: importance for pharmaceutical drug development. Lennernäs H Mol Pharm; 2014 Jan; 11(1):12-23. PubMed ID: 24206063 [TBL] [Abstract][Full Text] [Related]
76. G.L. Amidon, H. Lennernas, V.P. Shah, and J.R. Crison. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability, Pharm Res 12, 413-420, 1995--backstory of BCS. Shah VP; Amidon GL AAPS J; 2014 Sep; 16(5):894-8. PubMed ID: 24961917 [TBL] [Abstract][Full Text] [Related]
77. BCS class IV drugs: Highly notorious candidates for formulation development. Ghadi R; Dand N J Control Release; 2017 Feb; 248():71-95. PubMed ID: 28088572 [TBL] [Abstract][Full Text] [Related]
78. Variance based global sensitivity analysis of physiologically based pharmacokinetic absorption models for BCS I-IV drugs. Melillo N; Aarons L; Magni P; Darwich AS J Pharmacokinet Pharmacodyn; 2019 Feb; 46(1):27-42. PubMed ID: 30552544 [TBL] [Abstract][Full Text] [Related]
79. Novel high/low solubility classification methods for new molecular entities. Dave RA; Morris ME Int J Pharm; 2016 Sep; 511(1):111-126. PubMed ID: 27349790 [TBL] [Abstract][Full Text] [Related]
80. Evolution of Choice of Solubility and Dissolution Media After Two Decades of Biopharmaceutical Classification System. Bou-Chacra N; Melo KJC; Morales IAC; Stippler ES; Kesisoglou F; Yazdanian M; Löbenberg R AAPS J; 2017 Jul; 19(4):989-1001. PubMed ID: 28516359 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]